The autotransfusion process involves the reinfusion of the patient’s blood. Blood is collected from the peritoneal cavity or thorax region. The process can be carried out before surgery or during and after the surgery using the autotransfusion system. Medical procedures, like joint replacement, spinal surgeries, and cardiac, among others, require autotransfusion. It helps to reduce the risk of infection, and also it eliminates the problems and complications associated with the banking and administration of homologous donor blood. It helps to prevent the transmission of transfusion-related blood-borne diseases in patients.
The rapid spread of the COVID-19 pandemic has provided significant momentum to the autotransfusion device industry in 2020. SARS-CoV-2 (also known as COVID-19) has presented an unprecedented difficulty in several areas of medicine. Since, the beginning of the pandemic millions of patients worldwide have had their care delayed as hospitals canceled non-urgent operations, including some surgeries for people with heart and orthopaedic conditions. A very large number of operations were cancelled or postponed owing to disruption caused by COVID-19. Governments had mitigated against this major burden on patients by developing recovery plans and implementing strategies to restore surgical activity safely.
For Instance, according to British Journal of Surgery, an estimated 28,404,603 operations were cancelled or postponed during the peak 12 weeks of disruption due to COVID-19. The overall 12-week cancellation rate accounted to be 72·3%. Although elective surgeries resumed in the UK and many other countries in mid-2020, most hospitals were functioning at considerably reduced capacity, which translates to an ever-lengthening waitlist. As of September, 2020, nearly 140,000 patients in England alone had been waiting for more than a year for their surgeries—100 times the number in 2019. And with a new, highly transmissible variant of SARS-CoV-2 circulating in the UK, resulting in a third national lockdown and further cancellations, patients now face even longer waits.
The autotransfusion devices market is majorly comprised of top players such as BD, Braile Biomedica, Fresenius SE & Co. KGaA, Haemonetics Corporation, LivaNova PLC, Medtronic, Redax S.p.A., SARSTEDT AG and Co. KG, Teleflex Incorporated and Zimmer Biomet among others. The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the global autotransfusion devices market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]